Roggwil, April 28, 2020 – Resaphene Suisse AG, ISIN CH0367465439, WKN A2JG91, will lift the post-trade custody of shares in May 2020. After the shares have been booked from the investors' accounts, they can request a physical share certificate from the company with the last account statement.

For shareholders who already hold a physical share certificate, nothing changes.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been marketing a tinnitus therapy device under the name tinniwell since 2016. Since June 2018, the shares have been traded on the Vienna Stock Exchange in the Vienna MTF segment. Other distribution companies include Resaphene Deutschland GmbH in Constance, Resaphene UK Ltd. in London, and Resaphene US LLC

in the USA.

++ Contact for inquiries:

Resaphene Suisse AG

Bahnhofplatz 5

9322 Egnach

Switzerland

Investor Relations Contact:

Ms. Anke Rauterkus (Chief Executive Officer)

a.rauterkus@resaphene.ch